Toll-Like Receptor 3 Is a Mediator of the Innate Immune Response to Cytomegalovirus in Immature Dendritic Cells.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 731-731 ◽  
Author(s):  
Hermann Einsele ◽  
Michael Bonin ◽  
Florian Gebhardt ◽  
Tobias Kessler ◽  
Susanne Riegler ◽  
...  

Abstract Dendritic cells (DCs), contribute to the initiation of immune responses to viral infection. Toll-like receptors (TLRs) recognize pathogen-associated molecular patterns and initiate antimicrobial immune responses. TLR3 in DCs recognizes viral double-stranded RNA and triggers downstream signals to activate the NF?B and the interferon ß promoter. Double-stranded RNA may also be produced by double-stranded DNA viruses, such as HCMV, through bidirectional transcription from the genome during infection. Here we investigated whether TLR3 mediates the interaction between monocyte-derived immature DCs (iDCs) and HCMV after either active viral replication or viral penetration. We observed that HCMV strains differ in their interactions with iDCs. Strains that show no tropism for DCs, such as AD169, only penetrate iDCs, whereas the DC-tropic strains, e.g. TB40-E, actively replicate in iDCs. This difference provides an opportunity to study different forms of virus-DC interaction. Genome-wide expression array analysis showed that although 23 genes encoding cytokines, chemokines, and transcription factors are upregulated in iDCs after incubation with either strain, subsets of genes are induced specifically by DC-tropic or DC-nontropic strains. Only interaction with the DC-tropic HCMV strain TB40E, which replicates and produces mature virions, led to up-regulation of the TLR3 gene as well as genes downstream of TLR3 in the TLR3-signaling pathway, including class I interferon genes, NF?B, TRAF family member-associated NFKB activator (TANK), TANK-binding kinase 1 (TBK1), CXCL10, and CXCL11. The DC-nontropic HCMV strain AD169, which penetrates iDCs without replicating, did not upregulate genes of the TLR3 pathways. For selected genes, array data were confirmed by quantitative real-time PCR assay and ELISA to detect the gene products. To further confirm that the DC-tropic HCMV strain TB40E interacts with iDCs via TLR3, we transfected DCs with TLR3-specific siRNA prior to infection. TLR3 gene expression was potently silenced, while levels of the hALAS housekeeping gene mRNA remained normal. After these transfected DCs were infected with TB40E, HCMV-induced TLR3 gene expression was still markedly downregulated (−219 x), as were the downstream genes of the TLR3-signaling pathway (IFNa, −2.8 x; IFNß, −12.8 x; NF?B, −7.7 x; CCL5, −14.4 x; CXCL10, −16.5 x; CXCL11, −10.9 x). In contrast, TLR3 siRNA alone did not significantly modulate the expression of NF?B, CCL5, CXCL10, and class I interferons. Our results are consistent with those of McWirther et al., who reported that mice with a deficiency of TBK1 which is downstream of TLR3 show marked defects in IFNa and IFNß gene expression after viral infection or after engagement of TLR3 by double-stranded RNA. Thus, a key mediator of HCMV-DC interaction, which activates both a MyD88-dependent pathway that leads to early NF?B activation and a MyD88-independent pathway that leads to a class I interferon response (IFNa and IFNß) via interferon regulatory factor 3 (IRF3). This activation of the TLR3 signalling pathway was not observed when the DC-nontropic HCMV strain AD169 penetrated DCs without replicating. The identification of pathways that enhance innate antiviral immune responses may provide new avenues of therapeutic intervention for viral infections.

2003 ◽  
Vol 100 (19) ◽  
pp. 10872-10877 ◽  
Author(s):  
K. Honda ◽  
S. Sakaguchi ◽  
C. Nakajima ◽  
A. Watanabe ◽  
H. Yanai ◽  
...  

2022 ◽  
Vol 12 ◽  
Author(s):  
Valentina Ceglia ◽  
Sandra Zurawski ◽  
Monica Montes ◽  
Mitchell Kroll ◽  
Aurélie Bouteau ◽  
...  

CD40 is a potent activating receptor expressed on antigen-presenting cells (APCs) of the immune system. CD40 regulates many aspects of B and T cell immunity via interaction with CD40L expressed on activated T cells. Targeting antigens to CD40 via agonistic anti-CD40 antibody fusions promotes both humoral and cellular immunity, but current anti-CD40 antibody-antigen vaccine prototypes require co-adjuvant administration for significant in vivo efficacy. This may be a consequence of dulling of anti-CD40 agonist activity via antigen fusion. We previously demonstrated that direct fusion of CD40L to anti-CD40 antibodies confers superagonist properties. Here we show that anti-CD40-CD40L-antigen fusion constructs retain strong agonist activity, particularly for activation of dendritic cells (DCs). Therefore, we tested anti-CD40-CD40L antibody fused to antigens for eliciting immune responses in vitro and in vivo. In PBMC cultures from HIV-1-infected donors, anti-CD40-CD40L fused to HIV-1 antigens preferentially expanded HIV-1-specific CD8+ T cells versus CD4+ T cells compared to analogous anti-CD40-antigen constructs. In normal donors, anti-CD40-CD40L-mediated delivery of Influenza M1 protein elicited M1-specific T cell expansion at lower doses compared to anti-CD40-mediated delivery. Also, on human myeloid-derived dendritic cells, anti-CD40-CD40L-melanoma gp100 peptide induced more sustained Class I antigen presentation compared to anti-CD40-gp100 peptide. In human CD40 transgenic mice, anti-CD40-CD40L-HIV-1 gp140 administered without adjuvant elicited superior antibody responses compared to anti-CD40-gp140 antigen without fused CD40L. In human CD40 mice, compared to the anti-CD40 vehicle, anti-CD40-CD40L delivery of Eα 52-68 peptide elicited proliferating of TCR I-Eα 52-68 CD4+ T cells producing cytokine IFNγ. Also, compared to controls, only anti-CD40-CD40L-Cyclin D1 vaccination of human CD40 mice reduced implanted EO771.LMB breast tumor cell growth. These data demonstrate that human CD40-CD40L antibody fused to antigens maintains highly agonistic activity and generates immune responses distinct from existing low agonist anti-CD40 targeting formats. These advantages were in vitro skewing responses towards CD8+ T cells, increased efficacy at low doses, and longevity of MHC Class I peptide display; and in mouse models, a more robust humoral response, more activated CD4+ T cells, and control of tumor growth. Thus, the anti-CD40-CD40L format offers an alternate DC-targeting platform with unique properties, including intrinsic adjuvant activity.


2021 ◽  
Vol 22 (17) ◽  
pp. 9228
Author(s):  
Guoshuai Cai ◽  
Mulong Du ◽  
Yohan Bossé ◽  
Helmut Albrecht ◽  
Fei Qin ◽  
...  

The current spreading coronavirus SARS-CoV-2 is highly infectious and pathogenic. In this study, we screened the gene expression of three host receptors (ACE2, DC-SIGN and L-SIGN) of SARS coronaviruses and dendritic cells (DCs) status in bulk and single cell transcriptomic datasets of upper airway, lung or blood of COVID-19 patients and healthy controls. In COVID-19 patients, DC-SIGN gene expression was interestingly decreased in lung DCs but increased in blood DCs. Within DCs, conventional DCs (cDCs) were depleted while plasmacytoid DCs (pDCs) were augmented in the lungs of mild COVID-19. In severe cases, we identified augmented types of immature DCs (CD22+ or ANXA1+ DCs) with MHCII downregulation. In this study, our observation indicates that DCs in severe cases stimulate innate immune responses but fail to specifically present SARS-CoV-2. It provides insights into the profound modulation of DC function in severe COVID-19.


Blood ◽  
2001 ◽  
Vol 98 (12) ◽  
pp. 3465-3472 ◽  
Author(s):  
Hiroyuki Matsue ◽  
Keiko Matsue ◽  
Masahiro Kusuhara ◽  
Tadashi Kumamoto ◽  
Ko Okumura ◽  
...  

Abstract Allogeneic immune responses, which are initiated by dendritic cells (DCs) of both donor and host origins, remain a major obstacle in organ transplantation. Presentation of intact major histocompatibility complex (MHC) molecules by allogeneic DCs and allogeneic peptides by syngeneic DCs leads to complex allogeneic immune responses. This study reports a novel strategy designed to suppress both pathways. A stable DC line XS106 (A/J mouse origin) was transfected with CD95L cDNA and fused with splenic DCs purified from allogeneic BALB/c mice. The resulting “killer” DC-DC hybrids: (1) expressed CD95L and MHC class I and class II molecules of both A/J and BALB/c origins, while maintaining otherwise characteristic surface phenotypes of mature DCs; (2) inhibited MHC class I– and class II–restricted mixed leukocyte reactions between the parental strains by triggering apoptosis of alloreactive T cells; and (3) abolished delayed-type hypersensitivity responses of A/J (and BALB/c) mice to BALB/c-associated (and A/J-associated) alloantigens when injected intravenously into A/J (and BALB/c) mice. The onset of graft-versus-host disease in (BALB/c × A/J) F1 hosts receiving A/J-derived hematopoietic cell transplantation was suppressed significantly (P < .001) by killer DC-DC hybrid treatment. These results form both technical and conceptual frameworks for clinical applications of CD95L-transduced killer hybrids created between donor DCs and recipient DCs in the prevention of allogeneic immune responses following organ transplantation.


1997 ◽  
Vol 109 (4) ◽  
pp. 580-585 ◽  
Author(s):  
Andrea Kolesaric ◽  
Georg Stingl ◽  
Adelheid Elbe-Bürger

2021 ◽  
Vol 64 (1) ◽  
Author(s):  
Jeongyeon Yoon ◽  
Miao Fang ◽  
Dowhan Lee ◽  
Minsu Park ◽  
Kook-Hyung Kim ◽  
...  

AbstractRNA interference (RNAi) is a regulatory mechanism of gene expression mediated by small RNAs. By using the RNAi technique, exogenous double-stranded RNA (dsRNA) designed to target mRNA, suppresses target gene expression levels in plants. In this study, we adopted the RNAi mechanism as a tool to protect plants from viruses. We designed and synthesized several dsRNAs targeting the pepper mottle virus (PepMoV) genes HC-Pro and NIb. When used on Nicotiana benthamiana plants, these dsRNAs protected the plant against viral infection over a specific period. By optimizing dsRNA and virus injection time, the protection efficiency of dsRNA by targeting virus genes could be maximized. It seems that exogenous dsRNA-derived RNA-induced silencing complex was able to defend the host against viral infection instantly. Furthermore, each dsRNA designed to target different regions within a transcript had varying levels of effects on virus survival in the host plants. When targeting the middle part of both the NIb and HC-Pro genes using the dsRNAs, the highest viral growth inhibitory effect was observed. An RLM-5′ RACE was performed using plant leaves infected with PepMoV after dsRNA treatment and it was observed that most of the mRNA cleavages occurred close to the 3′ part within the dsRNA target position on the mRNA. These results suggest that the dsRNA tool can be used as a plant vaccine platform for crop protection.


2000 ◽  
Vol 9 (6) ◽  
pp. 1-5 ◽  
Author(s):  
Linda M. Liau ◽  
Keith L. Black ◽  
Neil A. Martin ◽  
Steven N. Sykes ◽  
Jeff M. Bronstein ◽  
...  

Dendritic cells (DCs) are antigen-presenting cells that play a central role in the initiation and modulation of antitumor immune responses. In this pilot study, we investigated the ability of autologous DCs pulsed ex vivo with allogeneic major histocompatibility complex class I–matched glioblastoma peptides to stimulate host antitumor immune responses when injected as a vaccine. A patient with recurrent brainstem glioblastoma multiforme (GBM) received a series of three intradermal immunizations of antigen-pulsed DCs on an outpatient basis following surgical debulking of her posterior fossa tumor. Dendritic cell vaccination was well tolerated, and no clinical signs of autoimmunity or experimental allergic en-cephalomyelitis were detected. She developed a measurable cellular immune response against the allogeneic glioblastoma peptides used in her vaccine preparation, as demonstrated by in vitro T-cell proliferation assays. In addition, increased T-cell infiltration was noted within the intracranial tumor site in the biopsy sample obtained following DC vaccination. An objective clinical response, however, was not evident, and this patient eventually died 21 months after her disease was diagnosed. To our knowledge, this is the first patient with brain cancer ever to be treated with DC-based immunotherapy. This case illustrates that vaccination with DCs pulsed with acid-eluted glioblastoma peptides is feasible and can induce systemic antigen-specific immunity in a patient with recurrent GBM. Additional studies are necessary to determine the optimum DC doses and antigen loading conditions that may translate into clinical effectiveness and survival benefit for patients with brain tumors. Phase I trials for malignant glioma are currently underway.


eLife ◽  
2015 ◽  
Vol 4 ◽  
Author(s):  
Lian He ◽  
Yuanwei Zhang ◽  
Guolin Ma ◽  
Peng Tan ◽  
Zhanjun Li ◽  
...  

The application of current channelrhodopsin-based optogenetic tools is limited by the lack of strict ion selectivity and the inability to extend the spectra sensitivity into the near-infrared (NIR) tissue transmissible range. Here we present an NIR-stimulable optogenetic platform (termed 'Opto-CRAC') that selectively and remotely controls Ca2+ oscillations and Ca2+-responsive gene expression to regulate the function of non-excitable cells, including T lymphocytes, macrophages and dendritic cells. When coupled to upconversion nanoparticles, the optogenetic operation window is shifted from the visible range to NIR wavelengths to enable wireless photoactivation of Ca2+-dependent signaling and optogenetic modulation of immunoinflammatory responses. In a mouse model of melanoma by using ovalbumin as surrogate tumor antigen, Opto-CRAC has been shown to act as a genetically-encoded 'photoactivatable adjuvant' to improve antigen-specific immune responses to specifically destruct tumor cells. Our study represents a solid step forward towards the goal of achieving remote and wireless control of Ca2+-modulated activities with tailored function.


Sign in / Sign up

Export Citation Format

Share Document